Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc Intensification on HIV-1 Viral Latency in Newly Infected, Treatment-Naïve Patients Starting Raltegravir + Tenofovir/Emtricitabine
2008-006065-87Phase 3Completed
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of maraviroc in Human immunodeficiency virus infection type 1, sponsored by Fight AIDS and Infectious Diseases Foundation. Primary endpoint: Change in integrated and unintegrated HIV-1 DNA in PBMCs at week 48. Started Oct 2008; status: completed.
02
Drugs
maraviroc
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2008-006065-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006065-87.